Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 6;48(4):1-7.
doi: 10.1192/bjb.2023.71. Online ahead of print.

A tool for safer prescribing in vulnerable adults: the continuing development of the Medichec app and website

Affiliations
Review

A tool for safer prescribing in vulnerable adults: the continuing development of the Medichec app and website

Delia Bishara et al. BJPsych Bull. .

Abstract

Aims and method: Adverse effects are a common concern when prescribing and reviewing medication, particularly in vulnerable adults such as older people and those with intellectual disability. This paper describes the development of an app giving information on side-effects, called Medichec, and provides a description of the processes involved in its development and how drugs were rated for each side-effect. Medications with central anticholinergic action, dizziness, drowsiness, hyponatraemia, QTc prolongation, bleeding and constipation were identified using the British National Formulary (BNF) and frequency of occurrence of these effects was determined using the BNF, product information and electronic searches, including PubMed.

Results: Medications were rated using a traffic light system according to how commonly the adverse effect was known to occur or the severity of the effect.

Clinical implications: Medichec can facilitate access to side-effects information for multiple medications, aid clinical decision-making, optimise treatment and improve patient safety in vulnerable adults.

Keywords: Medichec; anticholinergic; dementia; medication; side-effects.

PubMed Disclaimer

Conflict of interest statement

Medichec is owned by SLaM, the employer of several of the authors. R.S. has received research support in the past 3 years from Janssen, GSK and Takeda. A.S. holds a tender from NHS England for undertaking Learning Disability and Autism Mortality Reviews (LeDeR). He has advised AC Immune, ProMIS Neuroscience, and Aelis Farma.

References

    1. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15: 15–28. - PubMed
    1. Sönnerstam E, Sjölander M, Lövheim H, Gustafsson M. Clinically relevant drug–drug interactions among elderly people with dementia. Eur J Clin Pharmacol 2018; 74: 1351–60. - PMC - PubMed
    1. Sheehan R, Horsfall L, Strydom A, Osborn D, Walters K, Hassiotis A. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open 2017; 7(8): e017406. - PMC - PubMed
    1. Grande G, Haaksma ML, Rizzuto D, Melis RJF, Marengoni A, Onder G, et al. Co-occurrence of cognitive impairment and physical frailty, and incidence of dementia: Systematic review and meta-analysis. Neurosci Biobehav Rev 2019; 107: 96–103. - PubMed
    1. Gray SL, Anderson ML, Hubbard RA, LaCroix A, Crane PK, McCormick W, et al. Frailty and incident dementia. J Gerontol Series A 2013; 68: 1083–90. - PMC - PubMed

LinkOut - more resources